Astra Zeneca Covid Vaccine Trials and Approvals

The AstraZeneca Covid vaccine trials were a crucial step in making the vaccine available to the public. The trials began in April 2020.

The vaccine was tested in multiple countries, including the UK, Brazil, and South Africa. It was administered to thousands of participants to assess its safety and efficacy.

The trials showed that the vaccine was highly effective in preventing severe illness and hospitalization due to Covid-19. The vaccine's efficacy rate was over 70% in some trials.

The results of the trials were submitted to regulatory agencies for review and approval. This led to the vaccine's emergency use authorization in several countries.

The AstraZeneca COVID-19 vaccine was developed in collaboration with the University of Oxford, with the goal of creating a vaccine that could be easily transported and stored.

Clinical trials for the vaccine began in April 2020 and involved over 30,000 participants across multiple countries, including the UK, Brazil, and South Africa.

The vaccine was found to be 70.4% effective in preventing severe illness and hospitalization due to COVID-19 in a Phase III trial.

The early development of a project is a crucial stage that lays the foundation for its success. This stage typically involves conceptualization and initial planning.

A clear and concise project proposal is essential during this stage, outlining the project's objectives, scope, and timeline. This document serves as a roadmap for the project's development and helps stakeholders understand the project's goals.

The initial project team is formed during early development, consisting of key personnel who will drive the project forward. Their expertise and experience are critical in shaping the project's direction.

Research and feasibility studies are conducted to ensure the project's viability and potential for success. This stage helps identify potential risks and challenges that can be mitigated or addressed.

Stakeholder engagement is vital during early development, as it helps build support and buy-in for the project. This can include meetings, surveys, or other forms of communication to gather feedback and input.

See what others are reading: Unemployment Rates during Covid

Key performance indicators (KPIs) are established to measure the project's progress and success. These metrics help the project team stay on track and make data-driven decisions.

The early development stage is often characterized by a high degree of flexibility, allowing for changes and adjustments to be made as needed. This flexibility helps ensure the project's success and adaptability.

Clinical trials were a crucial part of the vaccine's development, and they had their fair share of ups and downs.

AstraZeneca partnered with IQVIA in July 2020 to speed up clinical trials in the US, and by August 31, they had started enrolling adults for a 30,000-subject late-stage study.

The trials were halted worldwide on September 8 due to a possible adverse reaction in a UK trial participant.

Trials resumed on September 13 after AstraZeneca, Oxford, and UK regulators concluded it was safe to do so.

However, the US didn't resume clinical trials until October 23 due to a separate investigation by the FDA surrounding a patient illness.

The results of the COV002 phase II/III trial showed that immunity lasts for at least one year after a single dose.

The UK was the first country to issue a temporary or emergency approval for the Oxford–AstraZeneca vaccine, with the Medicines and Healthcare products Regulatory Agency (MHRA) approving it on 30 December 2020.

The European Medicines Agency (EMA) began reviewing the vaccine on 12 January 2021 and recommended granting a conditional marketing authorisation for people 18 years of age and older on 29 January 2021.

The EMA's recommendation was accepted by the European Commission on the same day, paving the way for the vaccine's use in the EU.

The UK was the first country to issue a temporary or emergency approval for the Oxford–AstraZeneca vaccine, with the Medicines and Healthcare products Regulatory Agency (MHRA) approving it on 30 December 2020.

The European Medicines Agency (EMA) began reviewing the vaccine on 12 January 2021, and recommended granting a conditional marketing authorisation for people 18 years of age and older on 29 January 2021.

On 30 January 2021, the Vietnamese Ministry of Health approved the AstraZeneca vaccine for use, becoming the first vaccine to be approved in Vietnam.

The vaccine has since been approved by several non-EU countries, including Argentina, Bangladesh, Brazil, the Dominican Republic, El Salvador, India, Israel, Malaysia, Mexico, Nepal, Pakistan, the Philippines, Sri Lanka, and Taiwan regulatory authorities for emergency usage.

South Korea granted approval of the AstraZeneca vaccine on 10 February 2021, recommending the two-shot regimen for all adults, including the elderly.

The World Health Organization (WHO) issued interim guidance on 10 February 2021, recommending the AstraZeneca vaccine for all adults, and the Strategic Advisory Group of Experts also considered use where variants were present, concluding there was no need not to recommend it.

The government and regulatory authorities in Australia and Canada granted approval for temporary use of the vaccine in February 2021, with Canada approving it again on 19 November 2021.

The South African government's decision to suspend the AstraZeneca vaccine rollout on February 7, 2021, was a significant event in the regulatory and approval process.

Researchers from the University of the Witwatersrand released interim data suggesting the vaccine provided minimal protection against mild or moderate disease infection among young people.

The decision was based on concerns about the vaccine's effectiveness against the Beta variant, particularly in preventing severe illness and death.

Katherine O'Brien, director of immunization at the WHO, felt it was "really plausible" the AstraZeneca vaccine could have a "meaningful impact" on the Beta variant.

The South African government subsequently cancelled the use of the AstraZeneca vaccine, which led to increased vaccine hesitancy across the West, even in countries that did not suspend the vaccine.

The European Union has a complex regulatory and approval process, but one thing is clear: it's not a single, unified system. Each EU country has its own regulatory framework, but there are some commonalities.

The EU has a centralized system for approving medical devices, with the European Commission's Medical Device Coordination Group (MDCG) playing a key role. The MDCG ensures that medical devices meet EU safety and performance standards.

The EU's Medical Device Regulation (MDR) came into effect in 2020, replacing the previous Medical Device Directive (MDD). The MDR introduced stricter rules for medical device manufacturers, including more rigorous testing and documentation requirements.

The MDR also introduced the concept of a "Unique Device Identifier" (UDI) for each medical device, which is used to track and identify devices throughout the EU. This helps to improve safety and reduce errors.

The EU's regulatory process for pharmaceuticals is similarly complex, with multiple agencies involved, including the European Medicines Agency (EMA) and the European Commission's Directorate-General for Health and Food Safety.

Indonesia temporarily halted the rollout of a vaccine in March 2021 due to a wait for more safety guidance from the World Health Organization.

This pause in vaccination efforts lasted until March 19, when the vaccine was resumed for use in Indonesia.

Malaysia initially approved the use of the AstraZeneca vaccine, but removed it from the mainstream vaccination programme due to public concerns about its safety in late April 2021.

The public was allowed to register for the vaccine on a voluntary basis, and all 268,800 doses of the initial batch were fully booked in just three and a half hours after registration opened for residents of Selangor and Kuala Lumpur.

A second batch of 1,261,000 doses was offered to residents of Selangor, Penang, Johore, Sarawak, and Kuala Lumpur, with 29,183 doses reserved for previously waitlisted registrants and 275,208 doses taken up by senior citizens during a 3-day grace period.

The remaining doses were then offered to those aged 18 and above, and were completely booked within an hour.

The Malaysian Government continued to offer care to individuals suffering from adverse effects of COVID-19 vaccines, including the AstraZeneca vaccine, as announced by Health Minister Dzulkefly Ahmad on 10 May 2024.

A report on the AstraZeneca vaccine's adverse effects was confirmed to be released by the Malaysian Government later in the week, as announced by Deputy Health Minister Lukanisman Awang Sauni on 13 May.

For more insights, see: Will Insurance Cover Covid Tests after May 11

The AstraZeneca COVID-19 vaccine has shown a vaccine effect of 94% for COVID-19-related hospitalization at 28-34 days post-vaccination.

The most common side effects of the vaccine are mild and short-term, including discomfort at the injection site, feeling generally unwell, tired, or feverish, or a headache, feeling sick or having joint or muscle pain.

Anaphylaxis and other allergic reactions are known side effects of the vaccine, with the European Medicines Agency (EMA) assessing 41 cases of anaphylaxis from around 5 million vaccinations in the United Kingdom.

The vaccine has also been associated with a rare but potentially fatal thrombosis with thrombocytopenia syndrome (TTS), mainly in younger female recipients.

Here is a list of some of the rare side effects associated with the vaccine:

The first dose of the Oxford–AstraZeneca vaccine was associated with a vaccine effect of 94% for COVID-19-related hospitalisation at 28–34 days post-vaccination.

This is based on a study of 5.4 million people in Scotland, where 490,000 participants were given the Oxford–AstraZeneca vaccine.

The majority of participants over the age of 65 were given the Oxford–AstraZeneca vaccine.

Combined results showed a significant vaccine effect for prevention of COVID-19-related hospitalisation, which was comparable when restricting the analysis to those aged ≥80 years (81%).

Safety updates are a crucial aspect of ensuring the well-being of individuals receiving the COVID-19 vaccine. The Oxford–AstraZeneca vaccine has undergone numerous safety updates throughout its development and deployment.

Periodic safety update reports have been conducted to assess the vaccine's safety profile. The first report was released on 29 December 2021 to 28 June 2022, and subsequent reports have been published on a regular basis. These reports provide valuable insights into the vaccine's safety and efficacy.

The most common side effects of the Oxford–AstraZeneca vaccine include mild or moderate reactions, such as discomfort at the injection site, feeling generally unwell, tired, or feverish, or a headache, feeling sick or having joint or muscle pain. These side effects are usually short-term and resolve on their own within a few days.

Blood clots in combination with low platelet levels (thrombocytopenia) are listed as a very rare side effect of the AstraZeneca vaccine. Most cases were observed in the first 3-4 weeks after vaccination. The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed a possible link between the AstraZeneca Covid-19 vaccine and these rare blood clots in April 2021.

The European Medicines Agency (EMA) has also assessed 41 cases of anaphylaxis from around 5 million vaccinations in the United Kingdom. Capillary leak syndrome is a possible side effect of the vaccine, and the EMA has listed Guillain-Barré syndrome as a very rare side effect of the Oxford–AstraZeneca COVID-19 vaccine.

Here is a list of possible side effects of the Oxford–AstraZeneca vaccine:

It's essential to note that the benefits of the vaccine continue to outweigh the risks for the vast majority of people. If you have any concerns about the safety of the Oxford–AstraZeneca vaccine, it's best to consult with a healthcare professional for personalized advice.

The Oxford-AstraZeneca vaccine showed somewhat reduced efficacy against infection with the Alpha variant, with 70.4% efficacy in absolute terms against Alpha versus 81.5% against other variants.

Despite this, the vaccine remained effective at preventing symptomatic infection from this variant, and vaccinated individuals infected symptomatically typically had shorter duration of symptoms and less viral load.

A notable concern arose that the E484K mutation, present in the Beta and Gamma variants, could evade the protection given by the vaccine, prompting the collaboration to adapt the vaccine to target these variants.

The collaboration was working to adapt the vaccine to target the Beta and Gamma variants, with the expectation that a modified vaccine would be available "in a few months" as a "booster" given to people who had already completed the two-dose series of the original vaccine.

AstraZeneca published a press release confirming the development of an AZD2816 COVID-19 variant vaccine candidate, based on the current Vaxzevria adenoviral vector platform but modified with spike proteins based on the Beta (B.1.351 lineage) variant.

Phase II/III trials of the AZD2816 vaccine candidate were underway, with 2849 volunteers participating from various countries, and parallel dosing of both the current Oxford-AstraZeneca vaccine and the variant vaccine candidate.

The trials aimed to switch to the AZD2816 vaccine candidate if approved by government regulators, with the government of Thailand already agreeing to deliver additional 60 million doses of AstraZeneca COVID-19 Vaccine in 2022.

The South African government initially secured an initial 1 million doses of the AstraZeneca vaccine, but subsequently cancelled its use and switched to the Janssen COVID-19 vaccine.

Vaxzevria, previously known as COVID-19 Vaccine AstraZeneca, has a pediatric investigation plan, identified as EMEA-002862-PIP01-20-M04.

This vaccine has undergone several direct healthcare professional communications (DHPC), indicating ongoing monitoring and updates from the manufacturer.

The id.DRIVE study, a brand-specific COVID-19 vaccine effectiveness study in Europe, was conducted to assess the vaccine's effectiveness against severe COVID-19 disease.

The Vaccine Effectiveness, Burden and Impact Studies (VEBIS) series includes multiple post-authorisation studies evaluating the vaccine's effectiveness, burden, and impact in various populations and settings.

Here are some of the VEBIS studies mentioned:

The Oxford–AstraZeneca COVID-19 vaccine uses a modified, replication-deficient chimpanzee adenovirus to deliver the spike protein of the SARS-CoV-2 virus.

This adenovirus vector is called ChAdOx1 and contains the full-length codon-optimised coding sequence of the spike protein.

The virus is replication-deficient because some of its essential genes required for replication were deleted and replaced by a gene coding for the spike protein.

The vaccine also includes a tissue plasminogen activator (tPA) leader sequence, which helps the spike protein be produced in the body.

Following vaccination, the adenovirus vector enters the cells and releases its genes, which are then transported to the cell nucleus.

The cell's machinery does the transcription from DNA into mRNA and the translation into spike protein, which is then recognized by the immune system.

The production of coronavirus spike protein within the body triggers the immune system to attack the spike protein with antibodies and T-cells if the virus later enters the body.

The approach to using adenovirus as a vector to deliver the spike protein is similar to the approach used by the Johnson & Johnson COVID-19 vaccine and the Russian Sputnik V COVID-19 vaccine.

The vaccine is marketed under the brand name Vaxzevria in the European Union, previously known as COVID-19 Vaccine AstraZeneca.

It was renamed from COVID-19 Vaccine AstraZeneca to Vaxzevria on March 25, 2021.

AstraZeneca manufactures Vaxzevria, along with other brand names such as COVID-19 Vaccine AstraZeneca and AstraZeneca COVID‐19 Vaccine.

You can find more information on Vaxzevria in the European Medicines Agency's (EMEA) pediatric investigation plan, reference number EMEA-002862-PIP01-20-M04.

Additionally, there are several post-authorisation studies listed, including the id.DRIVE study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe.

Some of the other post-authorisation studies include:

The AZD1222 development team is working on adapting the vaccine to be more effective against newer SARS-CoV-2 variants. This process involves redesigning the vaccine by switching the genetic sequence of the spike protein.

Manufacturing set-up and a small-scale trial are required before the adapted vaccine is available. The development team is aiming to have the adapted vaccine available in autumn.

The World Health Organization (WHO) has a background document on the AZD1222 vaccine, which provides more information on its development and safety.

Here are some key dates for the AZD1222 vaccine development:

AstraZeneca's Covid vaccine admission in February 2024 marked a significant turning point in public awareness about its potential side effects.

In a legal document, AstraZeneca acknowledged that its vaccine can, in very rare cases, cause TTS (Thrombosis with thrombocytopenia syndrome).